U.S. markets close in 3 hours 35 minutes
  • S&P 500

    4,637.51
    +70.51 (+1.54%)
     
  • Dow 30

    34,865.09
    +381.37 (+1.11%)
     
  • Nasdaq

    15,733.31
    +195.62 (+1.26%)
     
  • Russell 2000

    2,231.22
    +32.31 (+1.47%)
     
  • Crude Oil

    67.56
    +1.38 (+2.09%)
     
  • Gold

    1,787.40
    +10.90 (+0.61%)
     
  • Silver

    22.53
    -0.28 (-1.23%)
     
  • EUR/USD

    1.1325
    -0.0014 (-0.12%)
     
  • 10-Yr Bond

    1.4600
    +0.0170 (+1.18%)
     
  • GBP/USD

    1.3318
    +0.0017 (+0.13%)
     
  • USD/JPY

    112.8640
    -0.3160 (-0.28%)
     
  • BTC-USD

    58,527.93
    +1,556.01 (+2.73%)
     
  • CMC Crypto 200

    1,491.13
    +22.05 (+1.50%)
     
  • FTSE 100

    7,168.68
    +109.23 (+1.55%)
     
  • Nikkei 225

    27,935.62
    +113.86 (+0.41%)
     

Atea Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BOSTON, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, will participate in a virtual fireside chat at the 4th Annual Evercore ISI HealthCONx Conference on Wednesday, December 1, 2021 at 3:05 p.m. ET.

A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation.

About Atea Pharmaceuticals

Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging the Company’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, Atea is focused on the development of orally-available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) and respiratory syncytial virus (RSV). For more information, please visit www.ateapharma.com.

Contacts

Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
Barnes.jonae@ateapharma.com

Will O’Connor
Stern Investor Relations
212-362-1200
will.oconnor@sternir.com